Select Your Region
Global
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
- Cancer
Trial Status:
Completed
This trial runs in
Cities
- Arrington
- Barcelona
- Boston
- London
- Nashville
- New York
- Pamplona
- San Francisco
- Seoul
- St. Louis
- Toulouse
Trial Identifier:
NCT03333655 ML40108
Trial Summary
The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.
Hoffmann-La Roche
Sponsor
Phase 4
Phase
NCT03333655 , ML40108
Trial Identifier
Biopsy
Treatments
Neoplasms
Condition
Official Title
A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy
Eligibility Criteria
All
Gender
≥ 18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for >6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
- Availability of tissue sample.
Exclusion Criteria
- Pregnant, lactating, or intending to become pregnant during the study.
- Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.
For the latest version of this information please go to www.forpatients.roche.com